Alnylam Announces Preliminary Q4 And FY23 Global Net Product Revenues And Provides Additional Updates; Q4 Net Product Revenues For ONPATTRO And AMVUTTRA ~$79M And $175M; Q4 Net Product Revenues For GIVLAARI And OXLUMO ~$59M And $33M
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals, Inc. reported preliminary Q4 and FY23 global net product revenues, showing significant growth. Q4 revenues for ONPATTRO and AMVUTTRA were approximately $79M and $175M, respectively, while GIVLAARI and OXLUMO revenues were about $59M and $33M, respectively. Full year revenues for these products totaled $1,241M, a 39% increase from the previous year. Over 4,060 patients were on ONPATTRO or AMVUTTRA, and over 1,080 patients were on GIVLAARI or OXLUMO by year-end. Alnylam also reported a strong balance sheet with $2.4B in cash and investments. The company will discuss these results at the J.P. Morgan Healthcare Conference.
January 08, 2024 | 1:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals reported strong preliminary Q4 and FY23 revenue growth, with a 39% increase in annual product revenues and a solid balance sheet. The company's RNAi therapeutics are gaining traction with a growing patient base.
The positive preliminary revenue results indicate a strong financial performance and growing market acceptance of Alnylam's products, which is likely to be viewed favorably by investors. The increase in patient numbers and the company's strong cash position suggest a positive outlook, potentially leading to a short-term increase in stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100